Meeting NewsVideo

VIDEO: Anti-VEGF, ang-2 combination shows potentially longer duration in wet AMD

FORT LAUDERDALE, Fla. At the Retina World Congress, Carl D. Regillo, MD, director of the retina service at Wills Eye Hospital in Philadelphia, discusses results from the STAIRWAY and AVENUE phase 2 studies of faricimab combined with ranibizumab, which showed a potentially longer durability than anti-VEGF alone.

FORT LAUDERDALE, Fla. At the Retina World Congress, Carl D. Regillo, MD, director of the retina service at Wills Eye Hospital in Philadelphia, discusses results from the STAIRWAY and AVENUE phase 2 studies of faricimab combined with ranibizumab, which showed a potentially longer durability than anti-VEGF alone.

    See more from Retina World Congress